PD-1抑制剂联合靶向药物治疗晚期原发性肝癌的临床疗效及安全性研讨

Clinical Effect and Safety Discussion of PD-1 Inhibitor Combined with Targeted Drugs in Treatment of Advanced Primary Liver Cancer

目的分析晚期原发性肝癌采取PD-1抑制剂联合靶向药物治疗的应用效果。方法对于本院中晚期原发性肝癌患者进行选择,共计24例,应用双盲法分组,每组相同例数,分析组采取PD-1抑制剂联合靶向药物治疗,参比组使用靶向药物治疗,对比患者客观缓解率、肝功能(ALT、AST、TBIL)、不良反应(高血压、腹泻、掌趾红肿综合征、甲状腺功能减退)发生率。结果分析组治疗客观缓解率对比参比组更高,有显著指标对比差异(P<0.05)。治疗前,分析组肝功能(ALT、AST、TBIL)相比于参比组,指标对比相近(P>0.05);治疗后,分析组肝功能指标显著优于参比组,差异有统计学意义(P<0.05)。分析组不良反应(腹胀、腹痛、恶心呕吐、肝功能受损)发生率较参比组无升高,差异有统计学对比意义(P<0.05)。结论PD-1抑制剂联合靶向药物治疗晚期原发性肝癌能够提高客观缓解率,使患者肝功能改善,并没有增加患者的不良反应。

Objective To analyze application effect of PD-1 inhibitors combined with targeted drugs in treatment of advanced primary liver cancer.Methods The paper chose 24 patients with advanced primary liver cancer in our hospital,and divided them into two groups with double blind method.Each group had the same number of patients.Analysis group was treated with PD-1 inhibitor combined with targeted drug treatment,while control group with targeted drug treatment.Objectiv response rate,liver function(ALT,AST,TBIL),and incidence of adverse reactions(hypertension,diarrhea,palmar and phalangeal redness and swelling syndrome,hypothyroidism)was compared.Results Objectiv response rate of analysis group was higher than reference group,with significant difference in indicators(P<0.05).Before treatment,liver function(ALT,AST,TBIL)of analysis group was similar to reference group(P>0.05).After treatment,liver function indicators of analysis group were significantly better than reference group,with statistical significance(P<0.05).Incidence of adverse reactions(abdominal distension,abdominal pain,nausea and vomiting,and liver function damage)in analysis group was not higher than reference group,with statistical significance(P<0.05).Conclusion Combination of PD-1 inhibitors and targeted drugs can improve objective response rate,liver function of advanced primary liver cancer patients,without increasing adverse reactions.